Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May;102(5):680-686.
doi: 10.1136/bjophthalmol-2017-310916. Epub 2017 Sep 11.

Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial

Abdou Amza  1 , Boubacar Kadri  1 , Beido Nassirou  1 , Sun Y Cotter  2 , Nicole E Stoller  2 , Sheila K West  3 , Robin L Bailey  4 , Travis C Porco  2   5   6 , Bruce D Gaynor  2   5 , Jeremy D Keenan  2   5   6 , Thomas M Lietman  2   5   6 , Catherine E Oldenburg  2   5   6
Affiliations

Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial

Abdou Amza et al. Br J Ophthalmol. 2018 May.

Abstract

Background/aims: The WHO recommends 3-5 years of annual mass azithromycin distribution with at least 80% treatment coverage to districts with active trachoma prevalence over 10% among children. Here, we assess the efficacy of expanding the coverage target to at least 90% for trachoma control in a mesoendemic region of Niger.

Methods: Twenty-four communities were randomised to a single day of azithromycin distribution with a coverage target of 80% of the community or up to 4 days of treatment, aiming for greater than 90% coverage. Distributions were annual and individuals above 6 months of age were treated. Children under 5 years of age were monitored for ocular chlamydia infection and active trachoma.

Results: At baseline, ocular chlamydia prevalence was 20.5% (95% CI 9.8% to 31.2%) in the standard coverage arm and 21.9% (95% CI 11.3% to 32.5%) in the enhanced coverage arm, which reduced to 4.6% (95% CI 0% to 9.5%, p=0.008) and 7.1% (95% CI 2.7% to 11.4%, p<0.001) at 36 months, respectively. There was no significant difference in 36-month ocular chlamydia prevalence between the two arms (p=0.21). There was no difference in the rate of decline in ocular chlamydia between the two arms in a repeated measures model (p=0.80).

Conclusions: For annual mass azithromycin distribution programme to an entire community, there may be no additional benefit of increasing antibiotic coverage above the WHO's 80% target.

Trial registration number: NCT00792922, post-results.

Keywords: Child Health (paediatrics); Clinical Trial; Conjunctiva; Infection; Public Health.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Flow diagram of study communities
Figure 2
Figure 2
Antibiotic coverage among children 0–5 years during mass antibiotic distributions by study visit.
Figure 3
Figure 3
Prevalence of ocular chlamydia infection in children aged 0–5 years in communities randomized to standard (A) or enhanced (B) coverage. All communities received annual mass azithromycin treatment in all age groups. Each of the 24 communities was monitored biannually (grey curves) and the mean was calculated for all communities (black curve).
Figure 4
Figure 4
Prevalence of trachomatous inflammation—follicular (TF) in children aged 0–5 years in communities randomized to standard (A) or enhanced (B) coverage. All communities received annual mass azithromycin treatment in all age groups. Each of the 24 communities was monitored biannually (grey curves) and the mean was calculated for all communities (black curve).
See this image and copyright information in PMC

References

    1. World Health Organization. Report of the 17th Meeting of the WHO Alliance for the Global Elimination of Blinding Trachoma. Geneva: 2013. Nov, pp. 1–56.
    1. Yohannan J, Munoz B, Mkocha H, Gaydos CA, Bailey R, Lietman TA, et al. Can We Stop Mass Drug Administration Prior to 3 Annual Rounds in Communities With Low Prevalence of Trachoma? JAMA Ophthalmol. 2013;131:431–16. doi: 10.1001/jamaophthalmol.2013.2356. - DOI - PMC - PubMed
    1. Lakew T, House J, Hong KC, Yi E, Alemayehu W, Melese M, et al. Reduction and Return of Infectious Trachoma in Severely Affected Communities in Ethiopia. Ko AI, editor. PLoS Negl Trop Dis. 2009;3:e376–7. doi: 10.1371/journal.pntd.0000376. - DOI - PMC - PubMed
    1. Melese M, Chidambaram JD, Alemayehu W, Lee DC, Yi EH, Cevallos V, et al. Feasibility of Eliminating Ocular Chlamydia trachomatis With Repeat Mass Antibiotic Treatments. JAMA. 2004;292:721–725. - PubMed
    1. House JI, Ayele B, Porco TC, Zhou Z, Hong KC, Gebre T, et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster-randomisedtrial. The Lancet Elsevier Ltd. 2009;373:1111–1118. doi: 10.1016/S0140-6736(09)60323-8. - DOI - PubMed

Publication types

Associated data